RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
+15.7%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$973M
AUM Growth
+$973M
(+50%)
Cap. Flow
+$220M
Cap. Flow
% of AUM
22.62%
Top 10 Holdings %
Top 10 Hldgs %
66.39%
Holding
36
New
7
Increased
5
Reduced
7
Closed
2
Top Buys
| 1 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
$68.6M |
| 2 |
Enanta Pharmaceuticals
ENTA
|
$61.6M |
| 3 |
DYAX
DYAX CORPORATION
DYAX
|
$52.2M |
| 4 |
RPRX
Repros Therapeutics Inc.
RPRX
|
$25.5M |
| 5 |
Neurocrine Biosciences
NBIX
|
$18.8M |
Top Sells
| 1 |
Acadia Pharmaceuticals
ACAD
|
$22.4M |
| 2 |
TherapeuticsMD
TXMD
|
$11.5M |
| 3 |
DSCI
Derma Sciences, Inc. Common Stock (DE)
DSCI
|
$8.32M |
| 4 |
ENZ
Enzo Biochem, Inc.
ENZ
|
$6.62M |
| 5 |
Novavax
NVAX
|
$3.96M |
Sector Composition
| 1 | Healthcare | 84.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Sangamo Therapeutics
SGMO
$157M
| $94.4M | 6.77% | 5,222,053 -5,219 | -0.1% | -$94.4K |
|
|
ACHN
2
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $76.9M | 5.51% | 23,366,007 | – | – |
|
|
DRNA
3
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $68.6M | 4.92% | +2,428,571 | New | +$68.6M |
|
|
DYAX
4
DELISTED
DYAX CORPORATION
DYAX
| $66.8M | 4.79% | 7,436,470 +5,816,773 | +359% | +$52.2M |
|
|
5
TherapeuticsMD
TXMD
$12.8M
| $62.1M | 4.45% | 9,838,449 -1,821,659 | -16% | -$11.5M |
|
|
ISEE
6
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $62M | 4.45% | 1,737,856 +137,401 | +9% | +$4.9M |
|
|
7
Enanta Pharmaceuticals
ENTA
$180M
| $61.6M | 4.42% | +1,541,078 | New | +$61.6M |
|
8
Prothena Corp
PRTA
$441M
| $59.6M | 4.27% | 1,554,918 -86,249 | -5% | -$3.3M |
|
9
Arrowhead Research
ARWR
$3.05B
| $48.3M | 3.46% | 2,941,916 +892,696 | +44% | +$14.7M |
|
10
BioCryst Pharmaceuticals
BCRX
$1.74B
| $46M | 3.3% | 4,347,456 | – | – |
|
|
11
Novavax
NVAX
$1.21B
| $45M | 3.23% | 9,938,250 -873,638 | -8% | -$3.96M |
|
12
Dynavax Technologies
DVAX
$1.19B
| $32.3M | 2.32% | 17,883,954 | – | – |
|
|
VIRX
13
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $32.2M | 2.31% | 4,869,261 | – | – |
|
14
Xencor
XNCR
$580M
| $32M | 2.29% | 2,725,000 | – | – |
|
15
PTC Therapeutics
PTCT
$3.92B
| $25.7M | 1.84% | 981,761 +229,323 | +30% | +$5.99M |
|
|
RPRX
16
DELISTED
Repros Therapeutics Inc.
RPRX
| $25.5M | 1.83% | +1,439,048 | New | +$25.5M |
|
|
TSRO
17
DELISTED
TESARO, Inc.
TSRO
| $20.6M | 1.48% | 700,000 | – | – |
|
|
18
Neurocrine Biosciences
NBIX
$13.8B
| $18.8M | 1.35% | +1,169,084 | New | +$18.8M |
|
|
DSCI
19
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| $17M | 1.22% | 1,339,039 -655,837 | -33% | -$8.32M |
|
|
MRTX
20
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $12.5M | 0.9% | 656,767 | – | – |
|
|
BLUE
21
DELISTED
bluebird bio
BLUE
| $10.6M | 0.76% | 467,418 | – | – |
|
22
EyePoint Pharmaceuticals
EYPT
$797M
| $10.5M | 0.75% | 2,555,659 +1,368,051 | +115% | +$5.61M |
|
|
ITMN
23
DELISTED
INTERMUNE INC
ITMN
| $10.1M | 0.72% | +300,801 | New | +$10.1M |
|
|
FLXN
24
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $7.4M | 0.53% | +450,000 | New | +$7.4M |
|
|
25
Acadia Pharmaceuticals
ACAD
$4.38B
| $6.08M | 0.44% | 250,000 -919,898 | -79% | -$22.4M |
|